Lung disease, Idiopathic pulmonary fibrosis
MNKDMannKind CorporationCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for MNKD 201 (nintedanib DPI) in Lung disease, Idiopathic pulmonary fibrosis. The expected timing is based on the latest available company guidance and may change.
4/30/24 First patient enrollment in June 2024. 11/4/24- Positive Ph1 results. 8/6/25- Initiate Ph2 trial by YE 2025. 11/05/25:- INFLO Ph2 trial initiated. First patient enrollment expected Q1 2026 instead of YE 2025. 02/26/26:- INFLO-1 Ph1b enrollment ongoing with topline data expected in 2H 2026; INFLO-2 first patient now planned Q2 2026. 05/06/26:- INFLO-1 Ph1b Cohort 1 enrollment completed; topline IPF data expected Q3 2026; INFLO-2 FPI remains Q2 2026. 06/03/26:- INFLO-1 randomization complete; INFLO-2 enrolled first patient. INFLO-1 Ph1b data expected Q3 2026. 07/29/26:- INFLO-1 Ph1b topline positive; well tolerated. INFLO-2 global Ph2 trial actively enrolling. 08/05/26:- Positive INFLO-1 Ph1b data and INFLO-2 enrollment were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.